EGYPTIAN INTERNATIONAL PHARMACEUTICALS (EIPICO)
PHAR

EGX

Current Price
EGP
EGP (%)
Price Upon Recommendation
50.26 EGP
Target Price from Recommendation

55.30 EGP

+10.00%
Holding Period

From 6 to 12 months

Final Recommendation

Buy stock at the current price

Valid Until

October 18, 2025 at 11:59:59 PM

Risk Assessment

Medium

Confidence Score

72.00%

Potential Growth

12.50%

Investment Reason

PHAR is positioned in the resilient pharmaceutical sector, benefiting from steady demand for healthcare products in Egypt. The stock shows strong fundamentals and aligns with EGX's recent bullish trends, supported by sector-specific growth drivers.

Overview
Recent Performance

PHAR has shown stability with a current price of 50.26 EGP, trading near its 52-week high. Recent volatility is low, reflecting market confidence in its defensive sector positioning.

Economic Factors

Egypt's healthcare sector is prioritized in government spending, with rising public health initiatives. Inflation stability and currency reforms further support pharmaceutical demand.

Competitive Positioning

PHAR holds a strong market share in Egypt's generics market, with a robust pipeline of affordable medications. Its vertical integration reduces production costs, enhancing margins.

Analysis Summary

PHAR's defensive sector positioning, coupled with Egypt's healthcare growth and stable fundamentals, makes it a compelling buy. Target price reflects achievable growth amid EGX's positive momentum.

Key Points
  • Defensive healthcare sector shields against economic volatility
  • 12.5% growth potential with government healthcare spending boost
  • Current price near 52-week high signals market confidence
  • Vertical integration ensures cost efficiency and margin resilience
Recommendations